

=> d his

(FILE 'HOME' ENTERED AT 15:31:05 ON 18 JUL 2002)

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 15:31:27 ON 18 JUL 2002

SEA (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND (ETEC

6 FILE ADISALERTS
1 FILE ADISINSIGHT
1 FILE ADISNEWS
9 FILE AGRICOLA
1 FILE AQUASCI
2 FILE BIOBUSINESS
2 FILE BIOCOMMERCE
327 FILE BIOSIS
35 FILE BIOTECHABS
35 FILE BIOTECHDS
246 FILE BIOTECHNO
19 FILE CABA
14 FILE CANCERLIT
728 FILE CAPLUS
3 FILE CEABA-VTB
3 FILE CONFSCI
3 FILE DDFU
246 FILE DGENE
1 FILE DRUGNL
11 FILE DRUGU
1 FILE DRUGUPDATES
2 FILE EMBAL
275 FILE EMBASE
118 FILE ESBIOBASE
5 FILE FEDRIP
42 FILE FSTA
170 FILE GENBANK
13 FILE IFIPAT
3 FILE JICST-EPLUS
220 FILE LIFESCI
364 FILE MEDLINE
117 FILE PASCAL
1 FILE PHAR
1 FILE PHIN
7 FILE PROMT
383 FILE SCISEARCH
229 FILE TOXCENTER
226 FILE USPATFULL
1 FILE USPAT2
20 FILE WPIDS
20 FILE WPINDEX
1 FILE CBNB
9 FILE NLDB

L1 QUE (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND (ETEC

SEA L1 AND (VACCINE OR IMMUNOGEN)

6 FILE ADISALERTS
1 FILE ADISINSIGHT

1 FILE ADISNEWS
1 FILE AQUASCI
1 FILE BIOCOMMERCE
39 FILE BIOSIS
24 FILE BIOTECHABS
24 FILE BIOTECHDS
22 FILE BIOTECHNO
2 FILE CABA
2 FILE CANCERLIT
138 FILE CAPLUS
1 FILE CEABA-VTB
3 FILE DDFU
174 FILE DGENE
1 FILE DRUGNL
10 FILE DRUGU
1 FILE DRUGUPDATES
28 FILE EMBASE
17 FILE ESBIOBASE
1 FILE FEDRIP
3 FILE FSTA
1 FILE GENBANK
6 FILE IFIPAT
21 FILE LIFESCI
39 FILE MEDLINE
15 FILE PASCAL
1 FILE PHAR
6 FILE PROMT
34 FILE SCISEARCH
30 FILE TOXCENTER
166 FILE USPATFULL
1 FILE USPAT2
16 FILE WPIDS
16 FILE WPINDEX
1 FILE CBNB
0* FILE USAN
9 FILE NLDB

FILE 'CAPLUS, SCISEARCH, MEDLINE, BIOSIS, EMBASE, BIOTECHNO, DGENE,
TOXCENTER, LIFESCI, GENBANK' ENTERED AT 15:44:43 ON 18 JUL 2002

L2 3188 S (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND (ETEC OR
L3 526 S L1 AND (VACCINE OR IMMUNOGEN)
L4 351 DUPLICATE REMOVE L3 (175 DUPLICATES REMOVED)
L5 78 S L4 AND SUBUNIT
L6 551 S (CS4 OR (COLI (A) SURFACE (A) ANTIGEN) OR PILIN) AND ETEC
L7 185 S L6 AND (VACCINE OR IMMUNOGEN)
L8 100 S L6 AND CS4 (P) (VACCINE OR IMMUNOGEN)
L9 44 DUPLICATE REMOVE L8 (56 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 15:55:54 ON 18 JUL 2002

L9 ANSWER 10 OF 44 SCISEARCH COPYRIGHT 2002 ISI (R) DUPLICATE 6
AN 1998:178598 SCISEARCH
GA The Genuine Article (R) Number: YY555
TI Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli - Cholera toxin B subunit vaccine in Egyptian adults
AU Savarino S J (Reprint); Brown F M; Hall E; Bassily S; Youssef F; Wierzbak T; Peruski L; ElMasry N A; Safwat M; Rao M; Jertborn M; Svennerholm A M; Lee Y J; Clemens J D
CS USN, MED RES UNIT 3, PSC 452, BOX 127, FPO, AE 09835 (Reprint); USN, MED RES UNIT 3, CAIRO, EGYPT; EGYPTIAN MINIST HLTH, BANHA, EGYPT; NICHHD, NIH, BETHESDA, MD 20892; GOTHENBURG UNIV, GOTHENBURG, SWEDEN
CYA USA; EGYPT; SWEDEN
SO JOURNAL OF INFECTIOUS DISEASES, (MAR 1998) Vol. 177, No. 3, pp. 796-799.
Publisher: UNIV CHICAGO PRESS, 5720 S WOODLAWN AVE, CHICAGO, IL 60637.
ISSN: 0022-1899.
DT Article; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 14
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
AB Enterotoxigenic Escherichia coli (**ETEC**) is the leading cause of bacterial diarrhea in young children in developing countries. The safety and immunogenicity of a killed, oral **ETEC vaccine** consisting of whole cells plus recombinantly produced cholera toxin B subunit (rCTB) was evaluated in Egypt, which is endemic for **ETEC** diarrhea. Seventy-four healthy Egyptian adults (21-45 years old) were randomized and received two doses of the **ETEC/rCTB vaccine** (E003) or placebo 2 weeks apart. The frequency of adverse events after either dose did not differ by treatment group, and no severe adverse events were reported. After vaccination, peripheral blood IgA B cell responses to CTB (100%) and to **vaccine** colonization factor antigens CFA/I (94%), **CS4** (100%), CS2 (81%), and CS1 (69%) were significantly higher than response rates for the placebo group. These favorable results in Egyptian adults indicate that the **ETEC/rCTB vaccine** is a promising candidate for evaluation in younger age groups in this setting.
IN Altbaum Z; Levine M M; Barry E M
PA (UYMA-N) UNIV MARYLAND BALTIMORE.
PI WO 2001081582 A2 20011101 81p
AI WO 2001-US12914 20010420
PRAI US 2000-198686P 20000420
DT Patent
LA English
OS 2002-049280 [06]
AN AAM50343 Protein DGENE
AB The present sequence is that of the tip associated protein CsaE of enterotoxigenic Escherichia coli (**ETEC**) strain E11881A. CsaE is encoded by the csaE gene (see AAI70763) of the E. coli E11881A csa operon. This operon includes 5 contiguous genes, csaA-csaE, which encode the synthesis of **ETEC-CS4** pili. It has been expressed in attenuated Shigella strain CVD1204 guaBA, constructing the Shigella expressing **CS4** fimbriae **vaccine** strain CVD1204 (pGA2-**CS4**). The CsaE protein has a calculated mol.wt. of 40102.4 and a theoretical PI of 8.74. It shows homology to similar proteins from other **ETEC** fimbriae. Recombinant CsaA-CsaE polypeptides are used in claimed immunogenic compositions to generate an immune response in a subject. These prevent **ETEC** colonisation, and hence protect against diarrhoea.

L9 ANSWER 18 OF 44 DGENE (C) 2002 THOMSON DERWENT
AN AAM50342 Protein DGENE
TI New nucleotide sequence, useful as immunogenic agent for generating immune response against recombinant product of the operon, comprises csa operon which encodes enterotoxigenic Escherichia coli-**cs4** pili
IN Altbaum Z; Levine M M; Barry E M
PA (UYMA-N) UNIV MARYLAND BALTIMORE.
PI WO 2001081582 A2 20011101 81p
AI WO 2001-US12914 20010420
PRAI US 2000-198686P 20000420
DT Patent
LA English
OS 2002-049280 [06]
AN AAM50342 Protein DGENE
AB The present sequence is that of regulatory protein CsaD of enterotoxigenic Escherichia coli (**ETEC**) strain E11881A. CsaD is encoded by the disrupted csaD gene (see AAI70762) of the E. coli E11881A csa operon, and lacks the N-terminal 48 amino acid. The csa operon includes 5 contiguous genes, csaA-csaE, which encode the synthesis of **ETEC-CS4** pili. It has been expressed in attenuated Shigella strain CVD1204 guaBA, constructing the Shigella expressing **CS4** fimbriae **vaccine** strain CVD1204 (pGA2-**CS4**). Recombinant CsaA-CsaE polypeptides are used in claimed immunogenic compositions to generate an immune response in a subject. These prevent **ETEC** colonisation, and hence protect against diarrhoea.

L9 ANSWER 22 OF 44 DGENE (C) 2002 THOMSON DERWENT
AN AAW48316 peptide DGENE
TI Monoclonal antibody agglutinating Escherichia coli with **cs4**-CFA/I family protein - is useful in assays and for treatment or prophylaxis against illness arising from infection with E. coli bearing **CS4**-CFA/I family proteins
IN Cassels F; Lees A; Schuman R
PA (USSA) US DEPT OF THE ARMY.
(VIRI-N) VIRION SYSTEMS INC.
PI WO 9805687 A1 19980212 14p
AI WO 1997-US13477 19970801
PRAI US 1996-23075 19960802
DT Patent
LA English
OS 1998-145553 [13]
AN AAW48316 peptide DGENE
AB The present sequence represents an Escherichia coli family **cs4**-CFA/I **immunogen** consensus peptide. The present invention describes a new monoclonal antibody which binds exclusively and specifically to SAVALTYS, agglutinates bacteria bearing **CS4**-CFA/I family proteins and is produced by hybridoma 96-109FE8 IH11. The monoclonal antibody can agglutinate members of the Escherichia coli family CSA-CFA/I, since it was raised to a consensus peptide known to raise antibodies against proteins of all the CSA-CFA/I family. E. coli causing diarrhoea are grouped into five classes, of which enterotoxigenic (**ETEC**), to which the **CS4**-CFA/I family belong, are the most common and pose the greatest risk to travellers. **ETEC** E. coli cause high infant mortality and illness in adult travellers in developing countries. The antibody is useful in assays to detect/ identify organisms bearing **CS4**-CFA family proteins, by contacting cultures of organisms for sufficient time for interaction, and

determining whether a **cs4**-CFA/I family protein/antibody complex has formed. It can be included in compositions with a carrier appropriate for application to bacteria-containing growth media, optionally with a tag e.g. a fluorescing agent or colorometric tag, to assist identification of the complex. It can also be included in compositions with pharmaceutically acceptable carriers, especially saline, useful for treating or prophylaxing against illness arising from infection with bacteria bearing **cs4**-CFA/I family proteins

WEST Search History

DATE: Thursday, July 18, 2002

Set Name Query
side by side

Hit Count Set Name
result set

<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>	
L3	CS4 same (vaccine immunogen) 9 L3
L2	L1 and @ad<20000420 19 L2
L1	(CS4 or (coli adj surface adj antigen adj 4)) and (immunogen\$4 vaccine) 24 L1

END OF SEARCH HISTORY